Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Oncology · Adenocarcinoma of the Esophagus and Esophagogastric Junction

Treatment Strategy: Advanced and Metastatic Disease

At a Glance

Treatment for advanced esophageal and EGJ adenocarcinoma is highly personalized. Oncologists use specific biomarkers from your pathology report—such as HER2, PD-L1, CLDN18.2, and MSI-H—to select precise targeted drugs and immunotherapies tailored to fight your unique cancer.

When adenocarcinoma of the esophagus or esophagogastric junction (EGJ) is diagnosed as advanced or metastatic, the goals of care shift toward controlling the disease, extending your life, and maintaining your quality of life [1]. This is a marathon, not a sprint.

The most important thing to know is that your treatment is no longer “one-size-fits-all.” Instead, your care is driven by a biomarker decision tree. Using the “locks” (biomarkers) found in your pathology report, your oncologist can choose the precise “keys” (targeted drugs) to attack your specific cancer [2][3].

Step 1: The First-Line Foundation

For almost everyone, the journey begins with first-line therapy. This usually consists of a “backbone” of chemotherapy, but the additions to that backbone depend entirely on your biomarkers [2]:

If Your Cancer is HER2-Positive

About 15–20% of these cancers overproduce the HER2 protein [4].

  • The Plan: You will likely receive a “triplet” of therapy: Chemotherapy + Trastuzumab + Pembrolizumab (an immunotherapy) [5][6].
  • Why? This combination has become the modern standard because adding immunotherapy to the HER2-targeted drug helps the immune system recognize and destroy the cancer more effectively [7].

If Your Cancer is HER2-Negative

If you do not have the HER2 marker, your team looks at other biomarkers:

  • PD-L1 (The CPS Score): If your CPS score is high (typically ≥5\geq 5 or ≥10\geq 10), adding an immunotherapy like nivolumab or pembrolizumab to chemotherapy is the standard of care [8][9]. Research shows that patients with higher scores tend to get the most significant benefit from these drugs [10][9].
  • CLDN18.2 (A New Key): If your tumor has high levels of this protein (found in at least 75% of cells), you may be a candidate for a new drug called zolbetuximab [11][12]. Trials like SPOTLIGHT and GLOW showed that adding this drug to chemotherapy significantly improves survival [13][14].
  • MSI-H Status: If your tumor is Microsatellite Instability-High (MSI-H), it is highly “visible” to the immune system. Immunotherapy is extremely effective for this group and is a cornerstone of their care [15][16].

Crucial Safety Note for Immunotherapy: While immunotherapy is highly effective, it can cause your immune system to become overactive and mistakenly attack healthy organs. This can lead to immune-related adverse events (irAEs) such as pneumonitis (lung inflammation causing shortness of breath) or colitis (severe diarrhea). You must report any new symptoms to your medical team immediately, as these conditions require prompt intervention.

Step 2: What Happens if the Cancer Changes?

Cancers can be clever and find ways around your first treatment. If the cancer begins to grow again, your team moves to second-line therapy.

For those who are HER2-positive, a breakthrough drug called trastuzumab deruxtecan (brand name Enhertu) is now the preferred second-line choice [17]. Unlike older drugs, this is a “smart bomb” (an antibody-drug conjugate) that delivers a potent dose of chemotherapy directly into the HER2-positive cells [18][19]. It has shown remarkable success in shrinking tumors even after other treatments have stopped working [20].

Focusing on Your Well-Being

While these treatments are powerful, they require active side-effect management. For example, drugs like zolbetuximab are notorious for causing severe nausea and vomiting. It is extremely important that you strictly adhere to the pre-medication regimen your doctor prescribes before your infusions to prevent these side effects [21][22]. Always speak up about how you feel—your quality of life is a vital part of your treatment’s success [1].

Common questions in this guide

Why do they test for biomarkers before starting treatment for advanced EGJ adenocarcinoma?
Biomarker testing helps your oncologist identify specific proteins or genetic markers in your tumor, such as HER2, PD-L1, or CLDN18.2. This information acts as a decision tree to match you with targeted drugs or immunotherapies that are most likely to work for your specific cancer.
What is the standard treatment for HER2-positive esophageal adenocarcinoma?
For patients with high levels of the HER2 protein, standard first-line treatment usually combines chemotherapy with targeted therapies like trastuzumab and an immunotherapy such as pembrolizumab. This triplet combination helps the immune system better recognize and attack cancer cells.
What does a high CPS score mean for my treatment?
A high CPS score indicates that your tumor expresses high levels of PD-L1, a protein that interacts with your immune system. Patients with a high score often receive significant benefits from adding immunotherapies like nivolumab or pembrolizumab to their chemotherapy regimen.
How does the CLDN18.2 biomarker affect my treatment options?
If your tumor has high levels of the CLDN18.2 protein, you may be eligible for a newer targeted drug called zolbetuximab. This drug is added to chemotherapy and has been shown to significantly improve survival rates for patients with this specific biomarker.
What are the risks of using immunotherapy for esophageal cancer?
While highly effective, immunotherapy can cause your immune system to mistakenly attack healthy organs, leading to immune-related adverse events. This can cause dangerous inflammation in the lungs or colon, making it essential to report any new symptoms like shortness of breath or severe diarrhea to your medical team immediately.
What happens if my cancer stops responding to first-line treatment?
If the cancer begins to grow again, your team will switch you to a second-line therapy. For instance, if your tumor is HER2-positive, a highly targeted antibody-drug conjugate called trastuzumab deruxtecan (Enhertu) may be used to deliver potent chemotherapy directly into the cancer cells.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific 'CPS score,' how much benefit should I expect from adding immunotherapy to my chemotherapy?
  2. 2.Since my cancer is HER2-positive, why are we adding pembrolizumab to the trastuzumab/chemotherapy mix?
  3. 3.If we use zolbetuximab, how strictly will we adhere to a pre-medication regimen to manage the expected nausea?
  4. 4.What specific signs of 'immune-related adverse events' (irAEs) should I be watching for if I am on immunotherapy?
  5. 5.If my cancer progresses after the first line of treatment, will I be a candidate for 'Enhertu' (trastuzumab deruxtecan)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Therapeutic Advances in the Treatment of Gastroesophageal Cancers.

    Li JJ, Rogers JE, Yamashita K, et al.

    Biomolecules 2023; (13(5)) doi:10.3390/biom13050796.

    PMID: 37238666
  2. 2

    Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

    Ajani JA, D'Amico TA, Bentrem DJ, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(4)):393-422 doi:10.6004/jnccn.2023.0019.

    PMID: 37015332
  3. 3

    Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma.

    Fick CN, Dunne EG, Sihag S, et al.

    The Annals of thoracic surgery 2024; (118(1)):130-140 doi:10.1016/j.athoracsur.2024.02.021.

    PMID: 38408631
  4. 4

    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.

    Shah MA, Kennedy EB, Alarcon-Rozas AE, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(7)):1470-1491 doi:10.1200/JCO.22.02331.

    PMID: 36603169
  5. 5

    An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1).

    Seguchi K, Kawazoe A, Nakayama I, Shitara K

    Expert review of anticancer therapy 2026; 1-10 doi:10.1080/14737140.2026.2628069.

    PMID: 41640060
  6. 6

    Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights.

    Aoki Y, Nakayama I, Shitara K

    Current oncology reports 2025; (27(1)):15-29 doi:10.1007/s11912-024-01626-2.

    PMID: 39753814
  7. 7

    Immune checkpoint inhibitors with trastuzumab and chemotherapy in advanced HER2-positive gastric cancer: A systematic review and meta-analysis.

    de Moraes FCA, Moreira Rego LHR, de Paiva FA, et al.

    Critical reviews in oncology/hematology 2025; (216()):104975 doi:10.1016/j.critrevonc.2025.104975.

    PMID: 41046084
  8. 8

    Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

    Doki Y, Ajani JA, Kato K, et al.

    The New England journal of medicine 2022; (386(5)):449-462 doi:10.1056/NEJMoa2111380.

    PMID: 35108470
  9. 9

    The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis.

    Li JB, Lai MY, Lin ZC, et al.

    Cancer immunology, immunotherapy : CII 2024; (73(7)):132 doi:10.1007/s00262-024-03726-1.

    PMID: 38753055
  10. 10

    PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials.

    Formica V, Morelli C, Fornaro L, et al.

    ESMO open 2024; (9(11)):103967 doi:10.1016/j.esmoop.2024.103967.

    PMID: 39541621
  11. 11

    Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting.

    Zhou KI, Strickler JH, Chen H

    Journal of hematology & oncology 2024; (17(1)):73 doi:10.1186/s13045-024-01595-w.

    PMID: 39183320
  12. 12

    Clinical Pharmacology Profile of the Claudin 18.2 Antibody Zolbetuximab.

    Yang J, Yamada A, Shitara K, et al.

    Clinical pharmacokinetics 2025; (64(10)):1465-1476 doi:10.1007/s40262-025-01552-x.

    PMID: 40804604
  13. 13

    Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.

    Shah MA, Shitara K, Ajani JA, et al.

    Nature medicine 2023; (29(8)):2133-2141 doi:10.1038/s41591-023-02465-7.

    PMID: 37524953
  14. 14

    Claudin18.2 promote gastric cancer proliferation by activating MCM2/5.

    Zheng B, Fu M, Lou F, et al.

    Scientific reports 2026; (16(1)).

    PMID: 41730953
  15. 15

    Evolving Strategies in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Esophagogastric Adenocarcinoma.

    Balmaceda NB, Kim SS

    Current oncology reports 2025; (27(2)):81-94 doi:10.1007/s11912-024-01624-4.

    PMID: 39832053
  16. 16

    Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.

    Marabelle A, O'Malley DM, Hendifar AE, et al.

    Nature cancer 2025; (6(2)):253-258 doi:10.1038/s43018-024-00894-y.

    PMID: 39979665
  17. 17

    Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.

    Van Cutsem E, di Bartolomeo M, Smyth E, et al.

    The Lancet. Oncology 2023; (24(7)):744-756 doi:10.1016/S1470-2045(23)00215-2.

    PMID: 37329891
  18. 18

    Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

    Shitara K, Bang YJ, Iwasa S, et al.

    The New England journal of medicine 2020; (382(25)):2419-2430 doi:10.1056/NEJMoa2004413.

    PMID: 32469182
  19. 19

    Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.

    Mishima S, Shitara K

    Expert opinion on biological therapy 2021; (21(7)):825-830 doi:10.1080/14712598.2021.1912007.

    PMID: 33798395
  20. 20

    Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.

    Shitara K, Iwata H, Takahashi S, et al.

    The Lancet. Oncology 2019; (20(6)):827-836 doi:10.1016/S1470-2045(19)30088-9.

    PMID: 31047804
  21. 21

    Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice.

    Shimozaki K, Ooki A, Yamahata Y, et al.

    ESMO gastrointestinal oncology 2025; (7()):100128 doi:10.1016/j.esmogo.2024.100128.

    PMID: 41646495
  22. 22

    Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience.

    Shimozaki K, Ooki A, Fukuoka S, et al.

    Journal of cancer research and clinical oncology 2025; (152(1)):16 doi:10.1007/s00432-025-06406-4.

    PMID: 41413321

This page provides educational information on advanced treatments for esophageal and EGJ adenocarcinoma. Always consult your oncologist to discuss which targeted therapies are safest and most appropriate for your specific case.

Get notified when new evidence is published on Adenocarcinoma of the oesophagus and oesophagogastric junction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.